Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Single Dose CDX-6114 in PKU
NCT04085666Phase 1Completed
- Sponsor
- Nestlé
- Start
- Jun 2019
- Primary completion
- Jun 2020
- Modality
- Replacement Enzymes
- Countries
- 2
01
Overview
Phase 1, randomised, double-blind trial of CDX-6114 in phenylketonuria (PKU) (2 arms), sponsored by Nestlé. Primary endpoints: Change in concentration of post parandial plasma level of Phe at Day 8, Change in concentration of post parandial plasma level of CA at Day 8 and 4 more. Started Jun 2019; status: completed.
02
Drugs
CDX-6114
03
Conditions
phenylketonuria (PKU)
Beyond the preview
Go deeper on NCT04085666.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04085666.